Gut-and-brain signaling peptide: non-sulfated CCK-8 fragment (research form)

What this is

Cholecystokinin-8 (CCK-8) non-sulfated is the eight-amino-acid C-terminal fragment of cholecystokinin, a gut-and-brain peptide hormone first identified in 1928 as the substance in intestinal extracts that makes the gallbladder contract (Rehfeld 2017). The card's stored sequence DYMGWMDF is the non-sulfated form — a research tool used to study one of CCK's two receptors in isolation. The naturally bioactive version in the body carries a sulfate group on Tyr² and a C-terminal amide (DY(SO₃H)MGWMDF-NH₂); neither modification is captured in the raw 1-letter sequence, and removing the sulfate drops affinity at the CCK₁ receptor (CCKAR) by roughly three orders of magnitude (Cawston and Bhatt, British Journal of Pharmacology 2010). The sulfated, amidated form — Sincalide (brand name Kinevac) — has been FDA-approved for decades as a diagnostic agent for gallbladder imaging (Bracco Diagnostics, Kinevac prescribing information). Non-sulfated CCK-8 itself has no approved therapeutic use; it is a pharmacological tool.

History

Cholecystokinin was discovered in 1928 by Andrew Ivy and Eric Oldberg at Northwestern University, who fractionated intestinal mucosal extracts and identified a factor that caused gallbladder contraction in dogs — naming it from the Greek for "gallbladder-mover" (Rehfeld 2017). A separate intestinal activity, "pancreozymin," was described in 1943 by Harper and Raper for its ability to stimulate pancreatic enzyme secretion. In 1964, Viktor Mutt and Erik Jorpes at the Karolinska Institute demonstrated that the two activities resided in the same molecule, and in 1968 they published the 33-residue sequence (CCK-33) after processing roughly 20 kilometers of porcine small intestine — establishing the C-terminal homology with gastrin and identifying the sulfated tyrosine that proved essential for CCKAR activity (Rehfeld 2017).

The link to satiety came in 1973, when Gibbs, Young, and Smith at Cornell University Medical College showed that intraperitoneal CCK reduced food intake in rats — the founding experiment of gut-peptide satiety research and the intellectual lineage from which the modern GLP-1 obesity programs descend (Rehfeld 2017; Miller and colleagues, Frontiers in Endocrinology 2021). The human extension was published in 1981 by Kissileff, Pi-Sunyer, Thornton, and Smith, showing that intravenous CCK-8 at near-physiologic concentrations reduced food intake at a buffet meal in lean men.

The two receptor subtypes were pharmacologically distinguished in the 1970s–1980s and later cloned: CCKAR (CCK1R), expressed on gallbladder, pancreatic acini, and vagal afferents, is highly selective for sulfated CCK forms; CCKBR (CCK2R, identical to the gastrin receptor), expressed in brain and gastric parietal cells, binds sulfated and non-sulfated forms with comparable affinity (Rehfeld 2017; Cawston and Bhatt 2010). That receptor-subtype asymmetry is precisely what makes non-sulfated CCK-8 a useful research probe — it can engage CCK2R without meaningfully activating CCK1R.

Selective receptor ligands followed in the 1980s and 1990s — devazepide (L-364,718) as a CCK1R antagonist, L-365,260 as a CCK2R antagonist — and were used to dissect which receptor mediated which effect. The CCK2R antagonist L-365,260 was taken into early human pharmacokinetic and tolerability studies in healthy volunteers (Grasing and colleagues, Journal of Clinical Pharmacology 1996). In 1990, Bradwejn and colleagues showed that the four-residue C-terminal fragment CCK-4 induced panic attacks in patients with panic disorder, establishing the CCK-4 challenge as a robust experimental paradigm in human psychiatry.

What it does

At CCK2R (CCKBR, the gastrin receptor). Non-sulfated CCK-8 binds CCK2R with affinity comparable to the sulfated form and activates Gq-coupled signaling — phospholipase C, IP₃, intracellular calcium mobilization (Cawston and Bhatt 2010). CCK2R is expressed in the brain (cortex, hippocampus, hypothalamus, nucleus accumbens), on gastric enterochromaffin-like and parietal cells where it drives gastrin-like acid secretion, and in pancreas. The principal research use of non-sulfated CCK-8 is exactly this — to probe CCK2R-mediated biology without confounding activation of the peripheral CCK1R-mediated effects.

At CCK1R (CCKAR, the satiety/digestive receptor) — minimal activity. CCK1R binding requires the Tyr² sulfate for high-affinity engagement (Cawston and Bhatt 2010). Without the sulfate, CCK-8 is approximately 1,000-fold less potent at CCK1R, so at concentrations used for CCK2R research it does not meaningfully activate CCK1R. As a consequence, non-sulfated CCK-8 does not reproduce the canonical gallbladder-contracting, pancreatic-enzyme-releasing, or vagal-satiety-signaling actions of CCK that the sulfated, amidated form (Sincalide) is used clinically to evoke.

Satiety, via the sulfated form at CCK1R. The satiety signaling attributed to CCK is mediated by sulfated CCK released postprandially from duodenal and jejunal I-cells, acting on CCK1R on vagal afferent terminals; the vagal signal reaches the nucleus tractus solitarius in the brainstem and is relayed to hypothalamic feeding circuits (Miller and colleagues 2021). This is the CCK1R/vagal-afferent pathway that has been the prototype of peripheral gut-peptide-to-brain satiety signaling. The stored non-sulfated form does not engage this pathway productively.

CNS roles at CCK2R. In the brain, CCK acts on CCK2R to modulate anxiety, pain processing, and dopaminergic signaling in reward circuits. The most striking human-pharmacology demonstration is the CCK-4 panic-induction paradigm: intravenous bolus of the four-residue C-terminal fragment CCK-4 reliably triggers panic attacks in patients with panic disorder, with enhanced sensitivity compared to healthy controls (Bradwejn and colleagues 1990; Bradwejn and colleagues, Archives of General Psychiatry 1991). Selective CCK2R antagonists such as L-365,260 were tested as anxiolytics on the back of this work but did not achieve clinically meaningful efficacy (Grasing and colleagues 1996).

Pancreatic and biliary effects (sulfated CCK, via CCK1R). Postprandial CCK release contracts the gallbladder, relaxes the sphincter of Oddi, and stimulates pancreatic acinar enzyme secretion (amylase, lipase, proteases) — actions that underpin Sincalide's clinical role as a diagnostic provocative agent. CCK1R is also a gene of interest for gallstone susceptibility: CCK1R knockout mice show impaired gallbladder contractility and increased cholesterol cholelithogenesis (Wang and colleagues, Genes 2020). At physiologic research concentrations, non-sulfated CCK-8 does not reproduce these effects.

Evidence

• Cholecystokinin biology as a whole. Rehfeld (Frontiers in Endocrinology, 2017) reviewed CCK from its 1928 discovery through the molecular cloning of preproCCK and the pharmacological characterization of CCK1R and CCK2R, including the affinity asymmetry between the two receptors for sulfated versus non-sulfated CCK-8 that is the basis for the non-sulfated form's use as a CCK2R-selective tool.

• Therapeutic potential and SAR at CCK1R. Cawston and Bhatt (British Journal of Pharmacology, 2010) reviewed CCK1R as a drug target, summarising structure–activity relationships, agonist and antagonist programs for obesity and gastrointestinal disorders, and confirming the strict requirement of Tyr² sulfation for high-affinity CCK1R agonism.

• CCK in the nutritional continuum. Miller and colleagues (Frontiers in Endocrinology, 2021) reviewed CCK1R agonist development for obesity, characterising the consistent failure of chronic CCK1R agonism to deliver durable weight loss despite reproducible short-term satiety — a pattern attributed to receptor desensitization and tolerability limits.

• Feeding suppression in a vertebrate model. Tachibana and colleagues (Comparative Biochemistry and Physiology Part A, 2012) studied sulfated CCK-(26–33) — the sulfated counterpart of this card's sequence — in chicks, characterising the dependence of feeding-suppressive activity on Tyr sulfation and on CCK1R engagement via vagal-brainstem circuits.

• CCK2R antagonist tolerability in humans. Grasing and colleagues (Journal of Clinical Pharmacology, 1996) reported single- and multiple-dose pharmacokinetics and tolerability of the CCK2R antagonist L-365,260 in healthy volunteers, including measures of anxiety, hunger, and cognitive performance — an early example of CCK2R pharmacology in humans.

• CCK1R in gallstone biology. Wang and colleagues (Genes, 2020) reviewed CCK1R (Lith13) as a gallstone-susceptibility gene, with mouse knockouts showing impaired gallbladder contraction and increased cholesterol cholelithogenesis — independent confirmation of CCK1R's central role in gallbladder physiology.

• Radiolabeled CCK/gastrin peptides for CCK2R-expressing tumors. Roosenburg and colleagues (Amino Acids, 2011) reviewed development of radiolabeled CCK and gastrin analogs for imaging and therapy of CCK2R-positive tumors (notably medullary thyroid carcinoma) — an oncology-imaging application of CCK2R pharmacology distinct from the satiety and panic literature.

• CCK in anorexia nervosa. Cuntz and colleagues (PLoS ONE, 2013) examined postprandial CCK responses in anorexia nervosa, contributing to the literature on elevated/early satiety signaling in restrictive eating disorders.

Sincalide (sulfated CCK-8, brand Kinevac) is FDA-approved as a diagnostic provocation agent for cholescintigraphy — measuring gallbladder ejection fraction in suspected biliary dyskinesia and post-cholecystectomy biliary evaluation, and to accelerate small-bowel transit during radiographic examination (Bracco Diagnostics, Kinevac prescribing information). It is the only CCK-derived compound with an approved human indication. No CCK1R agonist or CCK2R antagonist has been approved for obesity, anxiety, panic disorder, IBS, or gastroparesis, despite multiple completed clinical programs through the 1990s and 2000s (Cawston and Bhatt 2010; Miller and colleagues 2021).

Myths and misconceptions

• "Non-sulfated CCK-8 causes gallbladder contraction and satiety like Sincalide." No. Gallbladder contraction, pancreatic enzyme secretion, and vagal-mediated satiety are CCK1R-driven effects, and CCK1R has an approximately 1,000-fold lower affinity for non-sulfated CCK-8 than for the sulfated form (Cawston and Bhatt 2010). At the concentrations used in CCK2R research, the non-sulfated peptide does not meaningfully activate CCK1R.

• "Sincalide is a therapeutic dose of CCK." Sincalide is a diagnostic agent used during cholescintigraphy to provoke gallbladder contraction so that ejection fraction can be measured. It is a one-time controlled IV infusion, not a chronic medication, and it has no approved weight-loss or therapeutic indication (Bracco Diagnostics, Kinevac prescribing information).

• "CCK is basically the same as GLP-1." Both are postprandial gut peptides that reduce food intake, but they act at distinct receptors with very different track records. CCK has a minutes-scale half-life and acts via the vagus on CCK1R; chronic CCK1R agonism has consistently failed in obesity trials due to tachyphylaxis and tolerability limits (Cawston and Bhatt 2010; Miller and colleagues 2021). GLP-1 receptor agonism, with engineerable long-acting analogs, has become the dominant gut-peptide class for obesity pharmacology.

• "The CCK and gastrin systems are entirely separate." They are not. CCK2R is the gastrin receptor; CCK and gastrin share the same C-terminal pentapeptide (-Gly-Trp-Met-Asp-Phe-NH₂), and at CCK2R both peptides have comparable activity (Rehfeld 2017). CCK2R agonists and antagonists used in CCK research therefore also act on gastrin-mediated gastric acid biology.

• "CCK-8 is the main form of CCK in blood." The dominant circulating form in human plasma is CCK-58, not CCK-8. CCK-8S predominates in central neurons. The reason CCK-8 is the most studied form pharmacologically is its convenience as a synthetic research peptide, not its plasma abundance (Rehfeld 2017).

Common questions

Why is Tyr sulfation so important at CCK1R but not at CCK2R? The sulfate on Tyr² engages a specific binding pocket in CCK1R that is critical for high-affinity binding; CCK2R's binding region accommodates the unsulfated tyrosine without major affinity loss (Cawston and Bhatt 2010). That structural difference is the molecular basis for the entire research utility of non-sulfated CCK-8.

Is Sincalide the same compound as the stored sequence on this card? No. Sincalide is the sulfated, α-amidated CCK-8: DY(SO₃H)MGWMDF-NH₂. The card's stored sequence (DYMGWMDF) is the non-sulfated, non-amidated form, used as a research probe for CCK2R-selective pharmacology. Sincalide is the FDA-approved diagnostic agent (Bracco Diagnostics, Kinevac prescribing information); the stored form is not a therapeutic.

Why isn't there a CCK weight-loss drug like Ozempic? The short answer is tachyphylaxis. Multiple CCK1R agonist programs through the 1990s and 2000s produced reproducible short-term satiety in clinical trials but did not deliver durable weight loss; chronic CCK1R exposure desensitizes the receptor, and the tolerability window is narrow (Cawston and Bhatt 2010; Miller and colleagues 2021). GLP-1R agonism, by contrast, is amenable to long-acting engineered analogs and durable receptor pharmacology — which is why GLP-1 became the gut-peptide obesity class.

Known effects

• Gallbladder contraction and pancreatic enzyme secretion — established at the sulfated CCK-8 form via CCK1R; Sincalide is the FDA-approved diagnostic agent. The non-sulfated stored form does not produce these effects at research concentrations.
• Vagal-mediated satiety signaling — established at sulfated CCK acting on CCK1R on vagal afferents; the non-sulfated form does not effectively engage this pathway (Miller and colleagues 2021).
• CCK2R activation in brain and gastric mucosa — applies to non-sulfated and sulfated CCK-8 alike; the basis for using the non-sulfated form as a CCK2R-selective research probe (Rehfeld 2017; Cawston and Bhatt 2010).
• Panic provocation in panic disorder (CCK-4 paradigm) — robust experimental human pharmacology with the four-residue C-terminal fragment, not a therapeutic effect (Bradwejn and colleagues 1990).
• No approved therapeutic indication for the non-sulfated form — research tool only.

Safety signals

The safety literature applies almost entirely to the sulfated, clinically used form (Sincalide). The non-sulfated form is a research peptide without human therapeutic use. Sincalide infusion can produce abdominal cramping (from gallbladder contraction), nausea, urgency to defecate, and transient flushing; rapid bolus infusion increases the incidence of severe abdominal pain, and slow infusion over an extended period is the recommended administration in cholescintigraphy (Bracco Diagnostics, Kinevac prescribing information). Sincalide is contraindicated in suspected acute biliary obstruction. The CCK-4 fragment, used as a panic-provocation challenge, induces panic attacks in susceptible individuals — by design, in a controlled research setting — and is not used outside that paradigm (Bradwejn and colleagues 1990).

Regulatory status

• US: Sincalide (sulfated CCK-8, Kinevac) is FDA-approved as a diagnostic agent for cholescintigraphy, post-cholecystectomy biliary evaluation, and to accelerate small-bowel transit during radiographic examination (Bracco Diagnostics, Kinevac prescribing information). Non-sulfated CCK-8 (the stored sequence) has no FDA-approved indication. No CCK1R agonist or CCK2R antagonist is FDA-approved for obesity, panic disorder, IBS, or gastroparesis.
• EU / other: Sincalide and equivalent synthetic CCK-8 diagnostic agents are approved in multiple jurisdictions for cholescintigraphy. No regulator has approved a chronic CCK-based therapeutic.
• WADA: CCK is not specifically named on the WADA Prohibited List; the broader S2 class (peptide hormones and growth factors) may capture peptide hormones used for performance or appetite modulation outside an approved indication. The diagnostic use of Sincalide in imaging is not a realistic anti-doping concern.

Related peptides

• /card/pep-10717 — Peptide YY: a gut-derived satiety hormone released postprandially from distal L-cells. CCK (acting via vagal CCK1R) and PYY (acting via Y2R on arcuate NPY neurons) represent two complementary but anatomically distinct gut-to-brain satiety signals.
• /card/pep-10760 — Ghrelin: the principal orexigenic gut peptide and counter-regulatory signal to CCK's postprandial satiety effect; preprandial ghrelin rise drives hunger while meal-induced CCK contributes to termination.
• /card/pep-10569 — GLP-2: another proglucagon-family gut peptide involved in intestinal physiology and adaptation (teduglutide is the clinically developed analog). Shares the broader gut-peptide-hormone family context with CCK.